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The McDonald criteria allow the use of MRI to provide evidence of dissemination in 
space and time to establish a diagnosis of multiple sclerosis (MS), including in 
people with a single clinical event, or clinically isolated syndrome (CIS) [1]. The 
original criteria published in 2001 were revised based on evidence from large, 
multicentre European studies [2]. The high sensitivity and specificity of the McDonald 
criteria for the development of clinically-definite MS (CDMS) has been confirmed in 
number of studies. The McDonald criteria allow for an earlier diagnosis of MS, 
potentially facilitating earlier initiation of disease-modifying treatment [3].  
 
There are several caveats when applying the McDonald criteria [1]. Firstly, the 
criteria should only be applied in people with a “typical” clinical presentation 
suggestive of MS (e.g. unilateral optic neuritis, bilateral internuclear 
ophthalmoplegia). Deciding what constitutes a typical (or atypical) clinical 
presentation is subjective, although a number of reviews and expert consensus 
statements are available to guide neurologists [4]. Secondly, MRI findings alone are 
not enough to diagnose MS – there must be objective clinical evidence of at least 
one central nervous system lesion. Finally care must be taken to exclude alternative 
diagnoses. These caveats are essential when applying the McDonald criteria, but 
are sometimes overlooked. 
  
In this issue of European Journal of Neurology Rosencranz and colleagues evaluate 
the performance of the McDonald criteria in a cohort of patients referred to their 
centre with a suspected first demyelinating event [5]. The strength of the paper is the 
use of unselected cohort of patients with suspected MS to test how the McDonald 
criteria perform in a “real-world” setting, rather than in highly selected cohorts from 
specialist MS centres, in which the MRI criteria for diagnosing MS were developed 
and validated [2]. The limitations include the retrospective design and the use of 
clinically-acquired data meaning that not all patients had a follow-up MRI, which is 
important for demonstrating dissemination in time. 
 
The major finding of the study is that over a follow-up period of 2 years, only 1 in 3 
CIS patients who fulfilled the McDonald 2010 developed CDMS. The remaining 
patients had MRI evidence of dissemination in space and time but did not experience 
a second clinical attack, at least at different site (some patients had recurrent 
symptoms i.e. clinically-probable MS, but weren’t included in this group). The 
specificity, accuracy and positive predictive value of the McDonald 2010 criteria was 
rather lower in this cohort that in previous studies (<70%) leading the authors to 
question the benefit of the McDonald criteria.  
 
Why did so few patients develop CDMS? The most important factor is the short 
duration of follow-up. Only half of CIS patients who develop MS have a second 
clinical attack in the first 2 years after disease onset, and so the number with CDMS 
will inevitably increase with time [3]. A small number of patients also received 
disease-modifying therapies, which are known to delay the onset of CDMS in CIS 
patients. Finally, the authors included patients who presented with non-specific 
sensory symptoms without objective neurological signs (in whom the rate of CDMS 
was particularly low) and cognitive presentations, which although well-described in 
MS are not “typical”. The McDonald criteria have not been validated for use in 
patients with non-specific neurological symptoms or in patients with atypical clinical 
presentations, in whom the pre-test probability of MS is much lower than in young 
adult patients with unilateral optic neuritis or a partial myelopathy. Somewhat 
reassuringly when the subgroup of patients without objective neurological signs were 
excluded from the analysis the performance of the McDonald criteria was similar. 
However, it remains imperative that the McDonald criteria only be applied in patients 
with a typical CIS presentation who have objective evidence of at least one lesion. 
Misdiagnosis of MS is a major contemporary issue in neurological practice. A recent 
prospective study from North America highlighted the inappropriate application of the 
McDonald in patients with symptoms not typical of demyelination and without 
objective evidence of a lesion as major contributors to MS misdiagnosis and 
mistreatment [6].  
 
Overall the findings of Rosencranz and colleagues do suggest that MS is diagnosed 
more often in CIS patients using the McDonald criteria, confirming previous 
observations [3, 7, 8]. A subgroup of CIS patients have MRI evidence of 
dissemination in space and time on MRI with no further relapses or accumulation of 
physical disability over follow-up periods as long as 20 years [7]. Changes to the 
diagnostic criteria may be identifying patients with milder forms of MS and this may 
favourably impact on the long-term prognosis of relapse-onset MS [8]. This is a 
reminder that the McDonald criteria are intended to be diagnostic rather than 
prognostic. There is an unmet need for robust prognostic markers that can help 
predict disease course in people with CIS and early MS, including the timing of a 
second clinical attack, relapse rates and long-term disability.  
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